Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.49 |
| ▸ | FLT1 | P17948 | 8/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.49 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055023 | 0.89 | FGFR1 (0.48) | FGFR1FLT1KDRPDGFRBCBFB | |
| SCHEMBL4296098 | 0.88 | FGFR1 (0.52) | FGFR1FLT1KDRPDGFRBCBFB | |
| SCHEMBL4294962 | 0.87 | FGFR1 (0.59) | FGFR1FLT1KDRPDGFRBCBFB | |
| SCHEMBL27520967 | 0.84 | FGFR1 (0.51) | FGFR1FLT1KDRPDGFRBNCF1 | |
| SCHEMBL1055259 | 0.82 | FGFR1 (0.58) | FGFR1FLT1KDRPDGFRBCBFB | |
| SCHEMBL3731117 | 0.78 | RAB9A (0.62) | FGFR1KDRPDGFRBCBFB | |
| SCHEMBL3380086 | 0.76 | FGFR1 (0.81) | FGFR1FLT1KDRPDGFRB | |
| SCHEMBL27579469 | 0.75 | SLC6A2 (0.41) | FGFR1FLT1KDRPDGFRBOPRL1 | |
| SCHEMBL3738422 | 0.75 | METAP2 (0.55) | FGFR1FLT1KDRCDK1RET | |
| SCHEMBL1048556 | 0.75 | CBFB (0.55) | KDRCBFBATRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| CN-100526312-C | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| CN-1692112-A | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| CN-1659165-A | Quinolinone derivatives | CHIRON CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| CN-1226283-A | Recombinant enzyme with dextranase activity | NOVO NORDISK AS (DK) | 1999-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | FGFR1 939/4885FLT1 2113/4885KDR 2670/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FLT1 95/4885KDR 198/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | FGFR1 3018/4885FLT1 4604/4885KDR 4671/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | FGFR1 1273/4885FLT1 2304/4885KDR 1508/4885 |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | FGFR1 352/4885FLT1 556/4885KDR 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.